The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an
integrin αvβ3
antagonist in combination with an HMG-CoA
reductase inhibitor and / or a
bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an
integrin αvβ3
antagonist in combination with an HMG-CoA
reductase inhibitor and / or a bisphophonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an
integrin αvβ3
antagonist, an HMG-CoA
reductase inhibitor, or a
bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and / or activity of integrin αvβ3, disorders associated with abnormal bone
metabolism, disorders associated with aberrant
angiogenesis and cancers, or conditions associated therewith, utilizing an
antibody that immunospecifically binds to integrin αvβ3 (e.g., VITAXIN®) in combination with an HMG-CoA reductase inhibitor and / or
bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an integrin αvβ3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and / or activity of integrin αvβ3, disorders associated with abnormal bone
metabolism, disorders associated with aberrant
angiogenesis and cancers, or conditions associated therewith.